CardiologyNowNews.org CardiologyNowNews.org
Font ResizerAa
  • Home
    • About
      • Message from the Editor-in-Chief
      • Mission Statement
      • Editorial Board
  • News
  • Topics
    • Acute Coronary Syndrome
    • Arrhythmia and Electrophysiology
    • Cardiovascular Imaging
    • Cardiovascular Intervention
    • Cardiovascular Prevention
    • Cerebrovascular Disease
    • Heart Failure
    • Peripheral Vascular Disease
    • Structural Heart Disease
    • Valvular Heart Disease
  • Educational Resources
    • WikiDoc
    • BAIM Grand Rounds
    • Clinical Trial Results
  • ACC
    • ACC 2017
    • ACC 2018
    • ACC 2019
    • ACC 2020
    • ACC 2021
    • ACC 2022
    • ACC 2023
    • ACC 2024
    • ACC 2025
    • ACC 2026
  • AHA
    • AHA 2017
    • AHA 2019
    • AHA 2021
    • AHA 2022
    • AHA 2023
    • AHA 2024
    • AHA 2025
    • AHA 2026
  • ESC
    • ESC 2017
    • ESC 2018
    • ESC 2019
    • ESC 2021
    • ESC 2022
    • ESC 2023
    • ESC 2024
    • ESC 2025
  • SCAI
    • SCAI 2017
    • SCAI 2018
  • Videos
CardiologyNowNews.org CardiologyNowNews.org
Font ResizerAa
Search
  • Home
    • About
  • News
  • Topics
    • Acute Coronary Syndrome
    • Arrhythmia and Electrophysiology
    • Cardiovascular Imaging
    • Cardiovascular Intervention
    • Cardiovascular Prevention
    • Cerebrovascular Disease
    • Heart Failure
    • Peripheral Vascular Disease
    • Structural Heart Disease
    • Valvular Heart Disease
  • Educational Resources
    • WikiDoc
    • BAIM Grand Rounds
    • Clinical Trial Results
  • ACC
    • ACC 2017
    • ACC 2018
    • ACC 2019
    • ACC 2020
    • ACC 2021
    • ACC 2022
    • ACC 2023
    • ACC 2024
    • ACC 2025
    • ACC 2026
  • AHA
    • AHA 2017
    • AHA 2019
    • AHA 2021
    • AHA 2022
    • AHA 2023
    • AHA 2024
    • AHA 2025
    • AHA 2026
  • ESC
    • ESC 2017
    • ESC 2018
    • ESC 2019
    • ESC 2021
    • ESC 2022
    • ESC 2023
    • ESC 2024
    • ESC 2025
  • SCAI
    • SCAI 2017
    • SCAI 2018
  • Videos
Follow US
AHA 2026News

CRISPR-Cas9 Gene Editing of ANGPTL3 Lowers Triglycerides in Severe Hypertriglyceridemia: Phase 1b CTX310 Trial

Nathan Kong MD
Share
6 Min Read

Key Points:

  • Severe hypertriglyceridemia (sHTG), defined as fasting triglycerides >500 mg/dL, increases the risk of acute pancreatitis and cardiovascular disease. ANGPTL3 inhibits lipases involved in triglyceride clearance.. CTX310 is a one-time, lipid nanoparticle-delivered CRISPR-Cas9 therapy designed to permanently inactivate the ANGPTL3 gene.
  • In this first-in-human phase 1b expansion cohort, 10 participants with sHTG, all with diabetes and a median baseline triglyceride level above 1,000 mg/dL, received a single intravenous infusion of CTX310.
  • At 30 days, CTX310 reduced ANGPTL3 by 65.3%, triglycerides by 62.8%, and non-HDL cholesterol by 50.9% on average, with no serious adverse events related to treatment.

Severe hypertriglyceridemia (sHTG), defined as fasting serum triglyceride levels exceeding 500 mg/dL, is associated with an increased risk of acute pancreatitis and cardiovascular disease. Angiopoietin-like protein 3 (ANGPTL3)is a hepatocyte-derived glycoprotein that lowers triglyceride-rich lipoprotein and LDL clearance by inhibiting lipoprotein lipase and endothelial lipase. Individuals with naturally occurring ANGPTL3 loss-of-function variants have lower lifetime levels of triglycerides and low-density lipoprotein cholesterol (LDL-C). CTX310 is a lipid nanoparticle-encapsulated CRISPR-Cas9 therapy that introduces a loss-of-function mutation in hepatic ANGPTL3 with a single infusion. In the phase 1a dose study of participants with a range of lipid profiles, 12-month follow-up data published in August 2026 showed mean reductions of 79% in ANGPTL3, 48% in triglycerides, and 53% in LDL-C in the highest-dose group, but only one participant in this dose group had sHTG.

The phase 1b study was a multicenter, open-label, disease-specific expansion of the first-in-human CTX310 trial, conducted at four sites in Australia, New Zealand, the United Kingdom, and the United States beginning in May 2024. Adults aged 18 to 75 years with serum triglycerides higher than 500 mg/dL, with or without clinical atherosclerotic cardiovascular disease (ASCVD), received a one-time intravenous infusion of CTX310 at a fixed dose of 40 mg (body weight <85 kg) or 50 mg (body weight ≥85 kg). One participant from the phase 1a cohort who received 56.5 mg was also included. The primary outcome was safety. Efficacy endpoints included percent change over time in ANGPTL3, triglycerides, LDL-C, apolipoprotein B (ApoB), non-high-density lipoprotein cholesterol (non-HDL-C), and directly measured triglyceride-rich lipoprotein cholesterol (TRL-C).

The results were presented as late-breaking science at the American Heart Association (AHA) Scientific Sessions on November 9, 2026. Among the 10 participants, the median age was 56.5 years, 60% were men, and all had diabetes. Three (30%) had a history of pancreatitis and two (20%) had clinical ASCVD. Median baseline triglycerides were 1,067.7 mg/dL (interquartile range 740.4 to 2,269.2), mean LDL-C was 59.9 mg/dL, and mean hepatic fat fraction was 20.2%. Most participants were already on lipid-lowering therapy, including fibrates (80%) and statins (70%).

At 30 days, mean ANGPTL3 levels decreased by 65.3% from baseline, triglycerides by 62.8%, TRL-C by 60.5%, non-HDL-C by 50.9%, ApoB by 23.4%, and LDL-C by 16.4%. All 10 participants had lower triglycerides at 30 days, with individual reductions ranging from 28.2% to 84.6%, corresponding to absolute decreases of 299 to 1,972 mg/dL. Nine participants had reductions in ANGPTL3 of 46.5% to 86.8%, while one participant had a 7.2% increase. CTX310 was generally well tolerated. One serious, non-treatment related adverse event occurred, a hospitalization for shoulder pain and a rotator cuff tear more than 6 months after infusion. Four participants (40%) had adverse events deemed related to CTX310, all grade 1 or 2, including one grade 2 infusion-related reaction consisting of mild low back pain within 30 minutes of infusion. There were no clinically significant elevations in AST or ALT and no cases of acute pancreatitis. Additional phase 1b cohorts in other lipid disorders are ongoing using the same dosing regimen.

Limitations of the study include its small sample size and open-label, single-arm design without a control group. Efficacy was reported at 30 days, and durability in this population is still being assessed. All participants had diabetes, which may limit generalizability to the broader sHTG population, and the study was not designed to assess clinical outcomes. Finally, as CTX310 produces a permanent genetic change, long-term safety will require extended follow-up.

Presenting the results, Dr. Ashish Sarraju concluded that “in participants with severe hypertriglyceridemia, one-time in vivo CRISPR-Cas9 mediated editing of the hepatic ANGPTL3 gene was safe and lowered serum TG levels.” Dr. Sarraju added that “gene-editing is early in its human trials, but the safety and efficacy in the current trial is promising and represents a new frontier for drug development for severe hypertriglyceridemia.”

TAGGED:AHA 2026ConferenceFeaturedNews
Share This Article
Copy Link Print
CardiologyNowNews.org CardiologyNowNews.org
Copyright - CardiologyNowNews
  • Contact Us
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?